All-Assay-Max2 pQSAR: Activity predictions as accurate as 4-concentration IC50s for 8,558 Novartis assays
Éric MartiniD, Valery R. PolyakoviD, Xiang‐Wei ZhuiD, Li TianiD, Prasenjit K. MukherjeeiD, Xin LiuiD
Abstract
Profile-QSAR (pQSAR) is a massively multi-task, 2-step machine learning method with unprecedented scope, accuracy and applicability domain. In step one, a \"profile\" of conventional single-assay random forest regression (RFR) models are trained on a very large number of biochemical and cellular pIC50 assays using Morgan 2 sub-structural fingerprints as compound descriptors. In step two, a panel of PLS models are built using the profile of pIC50 predictions from those RFR models as compound descriptors. Hence the name. Previously described for a panel of 728 biochemical and cellular kinase assays, we have now built an enormous pQSAR from 11,805 diverse Novartis IC50 and EC50 assays. This large number of assays, and hence of compound descriptors for PLS, dictated reducing the profile by only including RFR models whose predictions correlate with the assay being modeled. The RFR and pQSAR models were evaluated with our \"realistically novel\" held-out test set whose median average similarity to the nearest training set member across the 11,805 assays was only 0.34, thus testing a realistically large applicability domain. For the 11,805 single-assay RFR models, the median correlation of prediction with experiment was only R2 ext=0.05, virtually random, and only 8% of the models achieved our standard success threshold of R2 ext=0.30. For pQSAR, the median correlation was R2 ext=0.53, comparable to 4-concentration experimental IC50s, and 72% of the models met our R2 ext>0.30 standard, totaling 8558 successful models. The successful models included assays from all of the 51 annotated target sub-classes, as well as 4196 phenotypic assays, indicating that pQSAR can be applied to virtually any disease area. Every month, all models are updated to include new measurements, and predictions are made for 5.5 million Novartis compounds, totaling 50 billion predictions. Common uses have included virtual screening, selectivity design, toxicity and promiscuity prediction, mechanism-of-action prediction, and others.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 85
- FWCI
- 6.62
- Field percentile
- top 2%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Model Choice Metrics to Optimize Profile-QSAR Performance
Stewart He, Sookyung Kim, … Jonathan Allen·bioRxiv·Aug 22, 2022
- Transfer learning applied in predicting small molecule bioactivity
Li Tian, Hugh Hongkai Huang, … Junzhou Huang·bioRxiv·Jan 9, 2025
- Regression QSAR Models for Predicting HIV-1 Integrase Inhibitors
C. H. X. Ha, N. K. Lee, … X. W. Chee·bioRxiv·Feb 23, 2021
- Support Vector Machine based prediction models for drug repurposing and designing novel drugs for colorectal cancer
A. Sengupta, R. Kumar·bioRxiv·Oct 20, 2023
- Leveraging multiple data types for improved compound-kinase bioactivity prediction
Ryan Theisen, Tianduanyi Wang, … Anna Cichońska·Nature CommunicationsPeer-reviewed·Aug 31, 2024
- Development of a QSAR model to predict molecular inhibition of human STAT3
Joshua M. Patterson, Kimberly A. Milligan, Cherese Winstead·bioRxiv·Oct 29, 2021